For patients, this means potentially reducing the risk of diabetes-related complications and enhancing overall health
By activating GLP-1 receptors in the hypothalamus and brainstem, these analogs promote satiety, leading to reduced food intake and weight loss ( Studies as Network Meta-analysis and clinical trials have shown that GLP1-RA can achieve a statistically significant decrease in HbA1C compared to placebo, as well as a weight reduction ranging between 1.3 and 8.65 kg ( With regard to cardioprotection, several mechanisms have been proposed
Cannot increase to a higher dose Sometimes, people do not feel as much appetite reduction with semaglutide because they are not able to increase to a higher dose, or they may not tolerate higher doses due to side effects like nausea or stomach upset, says Karalis, RD
Expert Opin Pharmacother (2019) 20(5):50110
10.1016/j.atherosclerosis.2012.05.007